ClinicalTrials.gg
Drug

Futibatinib clinical trials

Also written TAS-120 and Lytgobi.

studies test it
21
open now
10
in phase 3
6
first study started
2014

How each study uses futibatinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the futibatinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
30 Sept 2022 · LYTGOBI · NDA 214801 (FDA, Drugs@FDA)
European Union
4 Jul 2023 · Lytgobi · EMEA/H/C/005627 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Futibatinib
19

Brand

Lytgobi
5

Development codes

TAS-120
16

Studies by the year they started

18 studies that test it; most in 2021 (5); 3 more planned to start later

Studies that test futibatinib, by start year
YearStudies
20141
20162
20181
20191
20202
20215
20232
20243
20261

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
14
Phase 3
6

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 10 · Other 11

Taiho Oncology, Inc. (9) · Northwestern University (2) · UNICANCER (2) · Institut National de la Santé Et de la Recherche Médicale, France (1) · Mayo Clinic (1) · Yuanquan Yang (1) · American Society of Clinical Oncology (1) · Taiho Pharmaceutical Co., Ltd. (1)

Often tested with

Tested in the same studies.

Ivosidenib (2) · Zanidatamab (2) · Trastuzumab (2) · Olaparib (2) · Nivolumab (2) · Atezolizumab (2) · Paclitaxel (1) · Ramucirumab (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 4, 2 in phase 3

Studies that test futibatinib, phase 3 first.

Studies

Open first, then newest update. How each study uses futibatinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 21

See all 21 studies that test futibatinib →

Given beside what is tested · 2 — futibatinib is usual care or a partner of the new treatment

Codes

What other systems call futibatinib · ClinicalTrials.gg INT001542

  • MeSH (NLM) C000713257futibatinibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 4B93MGE4ALFUTIBATINIBConfirmed FDA, NLM, Wikidata
  • Wikidata Q76791462futibatinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C114283FutibatinibOne source FDA
  • DrugBank DB15149One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.